Continuous Renal Replacement Therapy (CRRT) Market Size, Share & Industry Analysis, By Product Type (Systems and Consumables (Dialysates, Replacement Solutions, Filters, Catheters, and Others)), By Modality (Slow Continuous Ultra Filtration (SCUF), Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD), and Continuous Venovenous Hemodiafiltration (CVVHDF)), and Regional Forecast, 2025-2032

The global Continuous Renal Replacement Therapy (CRRT) market size was valued at USD 1.16 billion in 2024. The market is projected to grow from USD 1.25 billion in 2025 to USD 2.14 billion by 2032, exhibiting a CAGR of 8.0% during the forecast period.

Continuous Renal Replacement Therapy (CRRT) is a specialized form of dialysis designed for critically ill patients particularly those with Acute Kidney Injury (AKI) and hemodynamic instability. Unlike traditional intermittent hemodialysis, which is typically performed over a few hours multiple times a week, CRRT operates continuously for 24 hours a day. This gradual removal of waste products and excess fluids minimizes the risk of rapid hemodynamic changes that can occur with traditional dialysis methods. Additionally, CRRT mimics the natural functions of the kidneys by regulating water, electrolytes, and toxins through slow solute and fluid removal. This makes it particularly beneficial for managing patients with multiple organ failure in intensive care units (ICUs). Some of the major players in this market include Baxter, Fresenius Medical Care AG & Co. KGaA (Germany), and B Braun SE.

In the recent years, this procedure has gained significant attention due to the increasing prevalence of Acute Kidney Injury (AKI) and advancements in technology. Other factors attributable to the market growth include a rapidly growing number of ICU admissions across the world, rising incidence of sepsis-related acute kidney injury, and constant new product launches by key industry players.

• For instance, according to the U.S. Centers for Disease Control and Prevention (CDC) data published in August 2023, annually, 1 in 3 people dying in hospitals had sepsis during their hospitalization. Among the common complications in critically ill patients, sepsis-associated acute kidney injury (S-AKI) is prominent, contributing to the growing demand for this therapy. It is also linked with a high rate of morbidity and mortality.

Market Dynamics

Market Drivers

Growing Number of ICU Admissions coupled with Technological Advancements to Propel Market Growth

Globally, the incidence of acute kidney injury (AKI) is increasing, particularly among critically ill patients, which is surging the demand for CRRT.

• For instance, according to 2023 statistics published by the UK Renal Registry, there were nearly 683,136 acute kidney injuries in the U.K. in 2023 compared to 589,985 in 2022, witnessing a rise of around 15.8% during the period. This trend has been further exacerbated by the COVID-19 pandemic, which led to a notable increase in ICU admissions, as many patients developed AKI as a complication of the virus.

CRRT is particularly beneficial in these scenarios due to its ability to provide continuous renal support while maintaining hemodynamic stability, making it a preferred choice for managing critically ill patients. In addition to the rising patient admissions, technological advancements and the launch of new technologies are significantly contributing to the growth of the market. As demand for CRRT increases due to a rising number of patients with acute kidney injury (AKI) and other renal conditions, manufacturers are focusing on developing innovative solutions that enhance treatment efficacy and patient outcomes.

• For instance, in May 2021, Baxter introduced  PrisMax2, the latest version of its CRRT system. This system also offers new solutions for the management of acute respiratory dysfunction along with the delivery of CRRT. Such key technological improvements are expected to boost market growth.

Market Restraints

High Upfront Cost Compared to Other Renal Replacement Therapies to Impede Growth Prospects

The high upfront costs associated with CRRT devices present a significant challenge to market growth. Compared to other renal replacement therapies, CRRT requires substantial investment in specialized equipment, consumables, and ongoing maintenance.

• For instance, according to a 2022 survey conducted by a U.S. healthcare payer, the daily cost of CRRT was estimated to be around USD 870.0, whereas the daily cost of intermittent hemodialysis (IHD) was nearly USD 270.0. These financial burdens can limit accessibility for healthcare facilities, especially in regions facing budget constraints or economic challenges.

Consequently, many hospitals may opt for more cost-effective alternatives, hindering the broader adoption of CRRT despite its clinical advantages in managing critically ill patients with acute kidney injury (AKI). Additionally, the preference for established dialysis methods can further impede the acceptance of CRRT, as healthcare providers may be reluctant to transition to a more expensive treatment option. These factors collectively pose significant barriers to market growth for CRRT.

Market Opportunities

Developing Devices for Pediatric AKI Patients to Offer New Opportunities

The development of specialized devices for pediatric patients with Acute Kidney Injury (AKI) presents new opportunities for the Continuous Renal Replacement Therapy (CRRT) market growth during the forecast period. With the increasing incidence of AKI among critically ill children, particularly in pediatric intensive care units (PICUs), there is a pressing need for tailored CRRT solutions that address the unique physiological characteristics of younger patients. Currently, CRRT machines are often not designed for smaller children, leading to a gap in effective treatment options.  Additionally, focusing on larger cohort clinical studies for the provision of CRRT to pediatric patients rather than using extrapolation of adult data can offer new opportunities.

Market Challenges

Lack of Skilled Healthcare Professionals and Regulatory Hurdles

The Continuous Renal Replacement Therapy (CRRT) market faces several challenges that impede its growth, primarily stemming from high costs, a shortage of skilled professionals, regulatory hurdles, and the complexity of setup. The high cost of CRRT devices, including machines, consumables, and ongoing maintenance, creates affordability issues, particularly in low-resource settings. Additionally, there is a notable lack of skilled healthcare professionals trained to operate CRRT equipment. The need for specialized training for nurses, technicians, and nephrologists is critical, yet many hospitals experience a shortage of personnel capable of managing these complex systems effectively. Moreover, regulatory hurdles present another barrier to market growth. The stringent approval processes for new CRRT technologies can delay market entry for innovative companies and startups, limiting competition and the introduction of potentially beneficial products.

• For instance, in September 2024, the U.S. FDA classified the pediatric CRRT system into class II (special controls) to ensure the safety and effectiveness of these devices.

The complexity of setting up CRRT poses challenges related to managing fluid balance, anticoagulation, and maintaining hemodynamic stability. These complexities can hinder broader adoption, particularly in resource-limited facilities.        

Market Trends

Technological Advancements in CRRT Systems and Increasing Preference of Continuous Venovenous Hemodiafiltration (CVVHDF) Modality

The CRRT market is experiencing significant growth driven by several interrelated trends, including technological advancements, the rising incidence of acute kidney injury (AKI), and an increasing focus on home-based and portable solutions. Technological advancements in CRRT systems have led to improved efficiency and automation, enhancing patient care in critical settings.

• For instance, according to an article published in BioMed Central Ltd in May 2023, continuous venovenous hemodiafiltration (CVVHDF) is increasingly being used for the treatment of AKI patients in ICU settings. This is used to correct electrolyte abnormalities, uremic milieu, and fluid imbalance.

Innovations in biocompatible materials and membranes, along with sophisticated fluid management systems, are making CRRT more effective for patients. Furthermore, the integration of remote monitoring and artificial intelligence (AI) enables real-time patient data analysis, facilitating timely interventions. The rise in AKI cases, largely attributed to chronic conditions such as diabetes, hypertension, and cardiovascular diseases, is driving demand for CRRT as more patients require renal support in intensive care units (ICUs). The increasing number of ICU admissions further amplifies this need. Additionally, there is a growing emphasis on home-based CRRT solutions and portable devices that allow patients with chronic conditions to receive treatment outside of hospital settings.

Impact of COVID-19

The COVID-19 pandemic had a notably positive impact on the global Continuous Renal Replacement Therapy (CRRT) market, as key players reported substantial revenue growth from their CRRT product lines due to a significant increase in patients requiring this therapy during the crisis.

• For instance, Baxter's Acute Therapies segment experienced a remarkable 38.3% revenue increase in 2020 compared to the previous year, reaching USD 740 million. This surge was largely driven by the rising demand for CRRT systems to treat acute kidney injuries linked to the rising number of COVID-19 cases across the Americas, Europe, and Asia.

Additionally, there was a notable increase in demand for CRRT systems as kidney failure emerged as a common complication among COVID-19 patients, leading to higher sales of CRRT consumables during this period. The rising prevalence of AKI in the general population, along with increasing awareness of advanced therapies and increased adoption of CRRT systems, is expected to fuel market growth during the forecast period.

Segmentation Analysis

By Product Type

Consumables Segment Dominated the Market Owing to Strong Demand for These Products

Based on product type, the market is divided into systems and consumables. The consumables segment is further sub-segmented into dialysates, replacement solutions, filters, catheters, and others.

In 2024, the consumables segment captured the largest market share, driven by several factors including relatively lower prices, the need for repetitive use, and the frequent purchases required for patients undergoing treatment for Acute Kidney Injury (AKI). Furthermore, the COVID-19 pandemic significantly boosted demand for consumables due to the rising incidence of AKI among COVID-19 patients. Additionally, the rising prevalence of Acute Kidney Injuries (AKI) continues to drive growth in this segment in the forecast period.

• According to a 2023 article published by the ScienceDirect, there were an estimated 13.3 million cases of acute kidney injury annually worldwide.

On the other hand, the systems segment is anticipated to witness a considerable growth throughout the forecast period. The growth is attributed to higher demand for technologically advanced systems in developed countries compared to the developing countries. In recent years, leading players have focused on the introduction of advanced products to tap into untapped market opportunities.

• For instance, in May 2021, Baxter introduced PrisMax 2, the latest version of its continuous renal replacement and organ support therapy system. The company aimed to launch this product in more than 20 countries to strengthen its market dominance.

By Modality

Continuous Venovenous Hemodiafiltration (CVVHDF) Segment Dominated Due to Increasing Preference of this Modality 

Based on modality, the market is segmented into Slow Continuous Ultra Filtration (SCUF), Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD), and Continuous Venovenous Hemodiafiltration (CVVHDF).

In 2024, the continuous venovenous hemodiafiltration (CVVHDF) segment accounted for the largest global continuous renal replacement therapy (CRRT) market share, driven by its optimal combination of diffusion and convection that allows for effective clearance of a wide range of solutes. The growing adoption of this modality among patients is further contributing to its market growth.

• For instance, a survey conducted by the Critical Care Nephrology Section of the European Society of Pediatric and Neonatal Intensive Care in 2022 indicated that 51% of respondents preferred continuous venovenous hemodiafiltration for their patients.

The continuous venovenous hemodialysis (CVVHD) segment is also projected to grow at a modest rate, benefiting from its advantages in continuously removing uremic toxins and fluids from patients. The demand for CVVHD is supported by its effectiveness in managing fluid overload and its adaptability to various patient needs. Overall, these trends indicate a robust outlook for CRRT modalities, particularly as healthcare providers seek effective treatments for the increasing prevalence of AKI among critically ill patients.

CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) MARKET REGIONAL OUTLOOK

On the basis of region, the global market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

North America held a dominant share in the market and generated a revenue of USD 0.46 billion in 2024. The rising prevalence of AKI in the U.S. and Canada along with growing adoption of various treatment options including CRRT among patients owing to the developed healthcare infrastructure are some of the primary reasons contributing to the growth of the market in the region.

The U.S. dominated the North American market in 2024. The rising pool of patients suffering from acute kidney diseases and the increasing focus of key players to introduce new products in the U.S. market are some of the major factors responsible for this dominance. For instance, in December 2020, Medtronic launched Carpediem cardio-renal pediatric dialysis emergency machine for pediatric and neonatal acute dialysis in the U.S. It is designed to provide continuous renal replacement therapy (CRRT) for patients with Acute Kidney Injury (AKI) or fluid overload, requiring hemofiltration and hemodialysis therapy.

Europe:

Europe accounted for the second-largest share in the global market. The growing number of patients suffering from various kidney disorders including acute kidney injuries and kidney failures, in countries such as the U.K. and Germany, along with increasing emphasis on treatment by healthcare organizations and government bodies, are expected to spur the growth of the market in the region.

• In Europe, according to the statistics of Kidney Care UK in June 2023, around 3.5 million people have chronic kidney disease. In the U.K., around 20 people develop kidney failure every day. These factors are expected to significantly contribute to the growth of the market in the region.

Asia Pacific:

The Asia Pacific region is expected to witness the fastest growth during the forecast period. In this region, countries such as Japan and China are expected to demonstrate considerable growth prospects. In Japan, the incidence of AKI accounts for approximately 40% of total ICU admissions and AKI contributes to around 26% of total in-hospital deaths in the country. This high incidence is expected to result in a high demand for renal replacement therapy in the region.

Latin America:

Latin America expected to witness considerable growth over the forecast period. Factors contributing to this growth include the rising adoption of continuous renal replacement therapy in ICU patients in Latin America region, increasing incidence of acute kidney injury in hospitalized patients, and increasing partnerships between domestic and global players in these regions to offer advanced products.

• For instance, in June 2020, CytoSorbents Corporation launched the CytoSorb blood purification technology in Latin America. The product was distributed in various Latin American countries during COVID-19 to treat patients grappling with life-threatening COVID-19 and acute kidney injury (AKI). This was used in association with CRRT to improve mortality rates amongst the patients.

Middle East & Africa:

The growing adoption of CRRT treatment among the population in South Africa, UAE, and other countries along with increasing healthcare facilities offering the treatment are expected to spur the growth of the market in the region. Additionally, rising Acute Kidney Injury (AKI) cases in the region is further boosting the segment's growth.

Competitive Landscape

Key Industry Players

Baxter to Lead due to Strong Product Offerings and Wider Distribution Network

The competitive scenario of this market reflects a consolidated market structure with leading players such as Baxter, Fresenius Medical Care AG & Co. KGaA, and B Braun SE accounting for a significant share in 2024.

Fresenius Medical Care, one of the leading players in the CRRT market, offers a comprehensive product portfolio that includes the PRISMAFLEX system. The company holds a significant market share and strategically positions itself through continuous innovation and its extensive global network of dialysis centers. Baxter plays a crucial role in the CRRT market with products such as the AK 98 CRRT machine, which features advanced fluid management and automated processes to enhance patient care. Innovations in this area have solidified Baxter's standing as a key competitor in the market.

Nipro Corporation provides various CRRT solutions and has established partnerships with hospitals to improve patient outcomes through collaborative efforts. Asahi Kasei Medical Co., Ltd. focuses on key product developments in CRRT and collaborates closely with healthcare providers to enhance treatment options. Medtronic is making strides in the CRRT space through technological advancements and strategic mergers and acquisitions. Other key players are persistently focusing on expanding their product offerings and entering acquisitions & strategic partnerships with other companies and healthcare providers in order to expand their customer base.

• For instance, in March 2022, B. Braun announced the acquisition of Intermedt Medizin & Technik GmbH. The acquisition would enhance the company's comprehensive range of products and services for dialysis therapy.

TRADE AND REGULATORY LANDSCAPE

The market for continuous renal replacement therapy (CRRT) devices is highly regulated, requiring approval from regional regulatory bodies before products can be marketed. In the U.S., CRRT devices are classified as Class II medical devices by the FDA, indicating a moderate risk associated with their use. This classification necessitates stringent regulatory oversight compared to Class I devices and typically requires premarket notification (510(k)), demonstrating that the device is substantially equivalent to a legally marketed device.

In Europe, CRRT devices must obtain CE marking, which requires compliance with the Medical Device Regulation (MDR) to ensure conformity with safety and performance requirements. Similar regulatory frameworks exist in other regions, ensuring that CRRT devices meet necessary quality standards before they enter the market.

FUTURE OUTLOOK AND MARKET FORECAST:

The market for CRRT is expected to grow at a CAGR of 8.0% between 2025 –2032. This growth is primarily driven by the increasing prevalence of acute kidney injury (AKI), particularly among the aging population. A rising number of ICU admissions due to chronic health conditions such as diabetes, hypertension, and cardiovascular diseases.

Technological advancements in CRRT systems, including innovations in fluid management and automation, are further contributing to market expansion. Furthermore, the growing emphasis on integrating CRRT into standard ICU protocols and the development of user-friendly devices are expected to enhance adoption rates, driving market growth further.

LIST OF KEY COMPANIES PROFILED:

• Baxter (U.S.)


• B Braun SE (Germany)


• Fresenius Medical Care AG & Co. KGaA (Germany)


• Asahi Kasei Medical Co., Ltd. (Asahi Kasei Corporation) (Japan)


• NIPRO (Japan)


• TORAY MEDICAL CO, LTD. (TORAY INDUSTRIES, INC.) (Japan)


• Nikkiso Co., Ltd. (Japan)


• Medtronic (Ireland)

Investment Analysis and Opportunities

KEY INDUSTRY DEVELOPMENTS

• December 2023 - Cheshire Medical Center, a member of Dartmouth Health, started offering Continuous Renal Replacement Therapy (CRRT) for ICU patients suffering from kidney failure.


• November 2023 - Horizon Health Network expanded its dialysis program to include Continuous Renal Replacement Therapy (CRRT) for patients at The Moncton Hospital (TMH).


• June 2023 – A professor from the University of Alabama at Birmingham received a grant of USD 3.8 million for the use of artificial intelligence (AI) in CRRT to predict outcomes in patients with acute kidney injury on continuous renal replacement therapy.


• January 2023: Peconic Bay Medical Center in Riverhead, New York started offering continuous renal replacement therapy for critically ill patients.


• January 2023: Baxter International Inc. announced a strategic roadmap to enhance its operational effectiveness. The plan includes spinning off its Renal Care and Acute Therapies global business units into an independent company.


• August 2022: Fresenius Medical Care North America introduced the Speedswap system for use with the NxStage System One with NxView. The system aimed to reduce downtime, lower treatment costs, and ease nursing workload in critical care settings.


• May 2020: Fresenius Medical Care AG & Co. KGaA received the Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for multiBic dialysate solutions to use in CRRT due to the acute care settings during the COVID-19 pandemic.

REPORT COVERAGE

The global continuous renal replacement therapy (CRRT) market report provides an in-depth analysis of the industry. It focuses on key aspects such as leading companies, product type, and modality. Besides this, the report offers insights into market trends, new product launches, key industry developments, and technological advancements. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the growth of the market in recent years. The report also provides the competitive landscape of the global market.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2024
Estimated Year	2025
Forecast Period	2025-2032
Historical Period	2019-2023
Growth Rate	CAGR of 8.0% from 2025-2032
Unit	Value (USD billion)
Segmentation	By  Product Type Systems Consumables Dialysates Replacement Solutions Filters Catheters Others
By Modality Slow Continuous Ultra Filtration (SCUF) Continuous Venovenous Hemofiltration (CVVH) Continuous Venovenous Hemodialysis (CVVHD) Continuous Venovenous Hemodiafiltration (CVVHDF)
By Region North America (By Product Type, By Modality, By Country) U.S. Canada Europe (By Product Type, By Modality, By Country/Sub-Region) U.K. Germany France Italy Spain Scandinavia Rest of Europe Asia Pacific (By Product Type, By Modality, By Country/Sub-Region) Japan China India Australia Southeast Asia Rest of Asia Pacific Latin America (By Product Type, By Modality, By Country/Sub-Region) Brazil Mexico Rest of Latin America Middle East & Africa (By Product Type, By Modality, By Country/Sub-Region) South Africa GCC Rest of Middle East & Africa